Making cancer care more effective and individualized is a central aim for cancer researchers worldwide. This is usually being pursued via DNA sequencing based efforts by the identification of oncogenic driver mutations. We believe and have emerging evidence that this will miss many therapeutic opportunities and additional endpoints including cell-based functional testing should be examined. Toward these goals, we carry out comprehensive ex vivo drug efficacy testing on patient-derived cells along with –omics profiling. We believe this approach will help to personalize treatment, aid in prioritizing drugs for clinical testing, provide for intelligent selection of drug combinations and improve treatment outcomes. Our work has a strong translational angle and is often carried out while the patient is receiving care. Our goal is to provide the treating clinician with additional treatment options should there be a need.
Initially we explored this functional drug testing platform in acute myeloid leukemia (AML) where the relevant material is more readily available. We have now also advanced to solid tumors including but not limited to ovarian, prostate and renal cancer. In solid tumors, relevant patient-derived ex vivo models are less readily available and the limited amount of tissue can be a challenge. Towards this we use different reprogramming methods of patient-derived primary cells in 2D, as well as 3D organoid cultures. We carry out genomics profiling of both tissue and model to ensure representativity of the cell models.
We have mapped the translational progress of our work into three phases, where phase I represents testing feasibility of model development. In phase II model development is doable, but representativity is still not optimal and no translation into treatment has been achieved. Phase III constitutes the final stage, where the cell models have generated actionable drugs that have been used in patient treatment. Our work is carried out in parallel both at the Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet in Stockholm, Sweden and at the Institute for Molecular Medicine Finland in Helsinki, Finland.
Olli Kallioniemi, Professor, Director SciLifeLab
Susanne Wikblad, PA, Admin
Päivi Östling, Associate Professor, Co-Principal Investigator
Brinton Seashore-Ludlow, Assistant Professor
Elisabeth Moussaud-Lamodiére, PhD, Senior lab manager
Sallinen Riitta, PhD, Project leader
Franscesco Marabita, PhD, Senior bioinformatician
Turkki Riku, PhD, Bioinformatician
James Tojo, PhD, Postdoctoral researcher
Sandra Jernström, PhD, Postdoctoral researcher
Tom Erkers, PhD, Postdoctoral researcher
Emilie Flaberg, PhD, MD stud, Postdoctoral researcher
Minozada Rezan, MSc, Labtechnician
Struyf Nona, MSc, Labtechnician
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.